CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients

CEL-SCI Corporation CVM has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell carcinoma of the head and neck (SCCHN).
In the intent to treat patients, the study showed a statistically significant overall survival benefit of 14.1% with overall survival of 62.7% at five years for the group of patients receiving the Multikine treatment regimen followed by surgery and radiotherapy therapy, but not chemotherapy, as part of their standard of care treatment.
The 3-year survival advantage was 4.9% (72.4% vs. 67.5%), and the 5-year survival advantage was 14.1% (62.7% vs. 48.6%) for the pre-defined population receiving no chemotherapy, versus standard of care alone.
No safety issues for Multikine were found during or due to its administration, including no late effects, in the overall treated patient population.
Multikine (Leukocyte Interleukin, Injection) is investigational cancer immunotherapy that contains 14 natural human cytokines, the body's immune system regulators.
Price Action: CVM shares are down 8.73% at $22.89 during the market session on the last check Monday.